We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cipher Pharma (CPH.TO)
An SI Board Since March 2019
Posts SubjectMarks Bans Symbol
6 1 0 CPH.TO
Emcee:  BioHero Type:  Moderated
Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year .

Cipher Pharmaceuticals (CPH.T)

Market Cap: $39.7 Million CAD
Cash $10.4 Million CAD
Price: $1.46

Shares Out: 26.8 Million

Slide Presentation

Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including:

Xydalba launch in first half of 2019

DTR-001 pre-clinical results in Q2 2019

Regulatory approval for plecanatide from Health Canada in Q4 2019

Regulatory approval for A-101 from Health Canada in Q4 2019

Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019

Largest Shareholder :

John Douglas Mull, MD 9,911,265
Grandeur Peak Global Advisors LLC 1,522,200
Taylor Asset Management, Inc. (Canada) 243,100
Harold Morton Wolkin, CFA 184,134
Arthur M. Deboeck 104,300
Mark A. Beaudet 87,790
Christian Godin 39,009
Robert D. Tessarolo 37,013
Stephen L. Lemieux, CPA 25,008

Acadian Asset Management LLC 9,093

 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):